𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A multicentric, randomized, double-blind, placebo controlled, dose response trial of LF 1695 in cured Hodgkin's desease

✍ Scribed by J.M. Lang; J.L. Kienzler

Publisher
Elsevier Science
Year
1988
Tongue
English
Weight
88 KB
Volume
10
Category
Article
ISSN
0192-0561

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
✍ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s

A double-blind, placebo-controlled singl
A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease
✍ Lisa Templeton; Andrew Barker; Keith Wesnes; David Wilkinson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional de®cits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

A 6-month, randomized, double-blind, pla
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease
✍ D.P. Devanand; Gregory H. Pelton; Karine Cunqueiro; Harold A. Sackeim; Karen Mar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 2 views

## Abstract ## Objective In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation. ## Methods In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of ha